CUMULATIVE SUPPLEMENT 4
JAN'88-APR'88



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

8TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS

with

THERAPEUTIC EQUIVALENCE EVALUATIONS

8TH EDITION

CUMULATIVE SUPPLEMENT 4

APRIL 1988

CONTENTS

APPROVED DRUG PRODUCTS

with

THERAPEUTIC EQUIVALENCE EVALUATIONS

8th EDITION

CUMULATIVE SUPPLEMENT 4

APRIL 1988

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 8th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products in the Division of Blood and Blood Products approved under Section 505 of the Act, and products discontinued from marketing or products which have had their approval withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product, along with the application number and product number (FDA's internal file number). All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.] The effective date for the approved drug product (the earliest date a product may be marketed) appears, when appropriate, to the left of the approval date.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item. A newly approved product is also identified by a lozenge (✖) to the right of its strength which remains throughout all Cumulative Supplements for this edition.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line containing overstruck print. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print will remain in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act and the Patent and Exclusivity Data will be dropped in subsequent Cumulative Supplements.

Products discontinued from marketing or products which have had their approval withdrawn for other than safety or effectiveness reasons, will be flagged in this Cumulative Supplement with the " ə " symbol to designate their non-marketed status. All products having a " ə " symbol in the 12th Cumulative Supplement of the 8th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 9th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (ointment;topical)	SEP 3, 1986 (51 FR 31371)
Nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 5, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

1.3 APPLICANT (NAME) CHANGES

Because it is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1987) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product, provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

COUNTS CUMULATIVE BY QUARTER[1]

CATEGORIES COUNTED	DEC 1987	MAR 1988	JUN 1988	SEP 1988
DRUG PRODUCTS LISTED	9709	9528*		
SINGLE SOURCE	2096 (21.6%)	1997 (21.0%)		
MULTISOURCE	7613 (78.4%)	7531 (79.0%		
THERAPEUTICALLY EQUIVALENT	6691 (68.9%)	6660 (69.9%)		
NOT THERAPEUTICALLY EQUIVALENT	848 (8.7%)	770 (8.1%)		
EXCEPTIONS[2]	74 (0.8%)	101 (1.0)		
NEW MOLECULAR ENTITIES APPROVED	--	1		
NUMBER OF APPLICANTS	349	361		

*This number is inclusive of products discontinued since December 1987, and any products approved or discontinued through March 1988.

(1) Cumulative counts are calculated from January 1, 1988 to, and including, the month indicated.

(2) Amino acid-containing products of varying composition (see Introduction, page I-8 of the List).

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, APAP, AND CAFFEINE

AB	HALSEY DRUG	325MG;50MG;40MG¤	N89536 001 FEB 16, 1988	> ADD > > ADD >

ACETAMINOPHEN; CODEINE PHOSPHATE

ELIXIR; ORAL

TYLENOL W/ CODEINE

/AA/	/MCNEIL LABS/	/120MG/5ML;12MG/5ML/	/N85057/001/
AA	MCNEIL PHARM	120MG/5ML;12MG/5ML	N85057 001

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	MUTUAL PHARM	300MG;15MG¤	N89671 001 FEB 10, 1988
AA		300MG;30MG¤	N89672 001 FEB 10, 1988
AA		300MG;60MG¤	N89673 001 FEB 10, 1988

TYLENOL W/ CODEINE

/AA/	/MCNEIL LABS/	/325MG;7.5MG/	/N85056/001/
/AA/		/325MG;15MG/	/N85056/002/
/AA/		/325MG;30MG/	/N85056/003/
/AA/		/325MG;60MG/	/N85056/004/
AA	MCNEIL PHARM	325MG;7.5MG	N85056 001
AA		325MG;15MG	N85056 002
AA		325MG;30MG	N85056 003
AA		325MG;60MG	N85056 004

TYLENOL W/ CODEINE NO. 1

/AA/	/MCNEIL LABS/	/300MG;7.5MG/	/N85055/001/
AA	MCNEIL PHARM	300MG;7.5MG	N85055 001

TYLENOL W/ CODEINE NO. 2

/AA/	/MCNEIL LABS/	/300MG;15MG/	/N85055/002/	
AA	MCNEIL PHARM	300MG;15MG	N85055 002	> ADD >

TYLENOL W/ CODEINE NO. 3

/AA/	/MCNEIL LABS/	/300MG;30MG/	/N85055/003/
AA	MCNEIL PHARM	300MG;30MG	N85055 003

TYLENOL W/ CODEINE NO. 4

/AA/	/MCNEIL LABS/	/300MG;60MG/	/N85055/004/
AA	MCNEIL PHARM	300MG;60MG	N85055 004

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

CO-GESIC

AA	CENTRAL PHARMS	500MG;5MG¤	N89360 001 MAR 02, 1988

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	LUCHEM PHARMS	500MG;5MG¤	N89696 001 APR 21, 1988	> ADD > > ADD >

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB	MYLAN PHARMS	65DMG;100MG¤	N72195 001 FEB 16, 1988

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	QUAD PHARMS	500MG/VIAL¤	N89619 001 JAN 13, 1988

DIAMOX

AP	LEDERLE LABS	500MG/VIAL	N09388 001

ALSEROXYLON

TABLET; ORAL

RAUTENSIN

/BP/	/DORSEY LABS/	/2MG/	/N09215/001/
	@ DORSEY LABS	2MG	N09215 001

AMINO ACIDS

INJECTABLE; INJECTION

TRAVASOL 10% IN PLASTIC CONTAINER

	BAXTER	10%¤	N18931 004 APR 27, 1988	> ADD > > ADD >

AMINOPHYLLINE

TABLET; ORAL
AMINOPHYLLINE

/BD/	/BARR/LABS/	/100MG/	/N88297/001/ /AUG/19,/1983/
	∂ BARR LABS	100MG	N88297 001 AUG 19, 1983
/BD/		/200MG/	/N88298/001/ /AUG/19,/1983/
	∂	200MG	N88298 001 AUG 19, 1983
	//3/VALE/CHEM/	/100MG/	/N84533/001/
BO	VALE CHEM	100MG	N84533 001

AMINOSALICYLATE SODIUM

TABLET; ORAL
TEEBACIN

/BP/	/CNSOL/MIDLAND/	/500MG/	/N07320/002/
	∂ CNSOL MIDLAND	500MG	N07320 002

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIL

/AB/	/PARKE/DAVIS/	/10MG/	/N83939/001/
/AB/		/25MG/	/N83937/001/
/AB/		/50MG/	/N83938/002/
/AB/		/75MG/	/N84957/001/
/AB/		/100MG/	/N85093/001/
/AB/		/150MG/	/N86295/001/
AB	WARNER CHILCOTT	10MG	N83939 001
AB		25MG	N83937 001
AB		50MG	N83938 002
AB		75MG	N84957 001
AB		100MG	N85093 001
AB		150MG	N86295 001

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

AB	PHARM BASICS	EQ 12.5MG BASE;5MG	N70477 001 JAN 12, 1988
AB		EQ 25MG BASE;10MG	N70478 001 JAN 12, 1988

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

AB	CLONMEL CHEMS	250MG	N62884 001 FEB 25, 1988
AB		500MG	N62881 001 FEB 25, 1988

POWDER FOR RECONSTITUTION; ORAL
POLYMOX

AB	BRSTL MYRS IND	125MG/5ML	N62885 001 MAR 08, 1988
AB		250MG/5ML	N62885 002 MAR 08, 1988

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL
AMPICILLIN

AB	CLONMEL CHEMS	EQ 250MG BASE	N62883 001 FEB 25, 1988
AB		EQ 500MG BASE	N62882 001 FEB 25, 1988

POLYCILLIN

AB	BRSTL MYRS IND	EQ 250MG BASE	N62888 001 MAR 04, 1988
AB		EQ 500MG BASE	N62888 002 MAR 04, 1988

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
COMPOUND 65

/AA/	/BANMAX/PHARMS/	/389MG;32.4MG;65MG/	/N84553/002/ /AUG/17,/1983/
	∂ BANMAX PHARMS	389MG;32.4MG;65MG	N84553 002 AUG 17, 1983

ASPIRIN; HYOROCODONE BITARTRATE

TABLET; ORAL
AZDONE

	CENTRAL PHARMS	500MG;5MG	N89420 001 JAN 25, 1988

BACLOFEN

TABLET; ORAL

> ADD > **BACLOFEN**

> ADD >	AB	VITARINE	10MG¤	N71901 001
> ADD >				APR 13, 1988
> ADD >	AB		20MG¤	N71902 001
> ADD >				APR 13, 1988

LIORESAL

> ADD >	AB	GEIGY PHARMS	10MG	N17851 001

LIORESAL DS

> ADD >	AB	GEIGY PHARMS	20MG	N17851 003
> ADD >				JAN 20, 1982

BENZTHIAZIDE

TABLET; ORAL

BENZTHIAZIDE

/BP/	/PRIVATE FMLTNS/	/50MG/	/N83206/001/
	∂ PRIVATE FMLTNS	50MG	N83206 001

BETAMETHASONE VALERATE

CREAM; TOPICAL

DERMABET

	AB	TARO PHARMS	EQ 0.1% BASE¤	N72041 001
				JAN 06, 1988

LOTION; TOPICAL

BETAMETHASONE VALERATE

> ADD >	AB	COPLEY PHARM	EQ 0.1% BASE¤	N71883 001
> ADD >				APR 22, 1988

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

> ADD > **BETHANECHOL CHLORIDE**

> ADD >	AP	QUAO PHARMS	5MG/ML¤	N89815 001
> ADD >				APR 12, 1988

URECHOLINE

> ADD >	AP	MS&D	5MG/ML	N06536 001

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

	AP	QUAO PHARMS	50MG/ML¤	N71181 001
				FEB 16, 1988

BROMPHENIRAMINE MALEATE

TABLET; ORAL

BROMPHENIRAMINE MALEATE

/AA/	/BARR LABS/	/4MG/		/N84468/001/
	∂ BARR LABS	4MG		N84468 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	KENDALL MCGAW	10MG/100ML;2.5GM/100ML;15MG/100ML; 300MG/100ML; 160MG/100ML¤	N19634 001
			FEB 24, 1988

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

	KENDALL MCGAW	4MG/100ML;4GM/100ML;6MG/100ML; 120MG/100ML;62MG/100ML¤	N19634 002
			FEB 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP	KENDALL MCGAW	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML; 310MG/100ML¤	N19634 003
			FEB 24, 1988

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	KENDALL MCGAW	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML¤	N19632 001
			FEB 29, 1988

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

AB	WARNER CHILCOTT	100MG¤		N71940 001
				FEB 01, 1988

TEGRETOL

AB	GEIGY PHARMS	100MG		N18281 001

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

CECLOR

>ADD>		LILLY	EQ 187MG BASE/5ML¤	N62206 003 APR 20, 1988
>ADD>			EQ 375MG BASE/5ML¤	N62206 004 APR 20, 1988

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

AP	SK&F LABS	EQ 5GM BASE/VIAL	N50461 004

CEFAZOLIN SODIUM

AP	ELKINS SINN	EQ 250MG BASE/VIAL¤	N62807 001 JAN 12, 1988
AP		EQ 500MG BASE/VIAL¤	N62807 002 JAN 12, 1988
AP		EQ 1GM BASE/VIAL¤	N62807 003 JAN 12, 1988
AP		EQ 5GM BASE/VIAL¤	N62807 004 JAN 12, 1988
AP		EQ 10GM BASE/VIAL¤	N62807 005 JAN 12, 1988
AP		EQ 20GM BASE/VIAL¤	N62807 006 JAN 12, 1988

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

>ADD>		STUART PHARMS	EQ 10GM BASE/VIAL¤	N50588 003 APR 25, 1988

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

AB		JEROME STEVENS	EQ 250MG BASE¤	N62870 001 MAR 17, 1988
AB			EQ 500MG BASE¤	N62869 001 MAR 17, 1988
AB		TAG PHARMS	EQ 250MG BASE¤	N62821 001 FEB 05, 1988
AB			EQ 500MG BASE¤	N62823 001 FEB 05, 1988

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL

CEPHALEXIN

>ADD>	AB	TAG PHARMS	EQ 250MG BASE/5ML¤	N62867 001 APR 15, 1988

CEPHRADINE

CAPSULE; ORAL

CEPHRADINE

>ADD>	AB	BARR LABS	250MG¤	N62850 001 APR 22, 1988
>ADD>	AB		500MG¤	N62851 001 APR 22, 1988
>ADD>	AB	VITARINE	250MG¤	N62813 001 FEB 25, 1988
	AB		500MG¤	N62813 002 FEB 25, 1988

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

/AB/	/PUREPAC/PHARM/	/5MG/	/N85155/001/
	a PUREPAC PHARM	5MG	N85155 001
/AB/		/10MG/	/N84939/002/
	a	10MG	N84939 002
/AB/		/25MG/	/N85144/001/
	a	25MG	N85144 001

LYGEN

/AB/	/BANMAX/PHARMS/	/5MG/	/N85107/002/
	a BANMAX PHARMS	5MG	N85107 002
/AB/		/10MG/	/N85009/001/
	a	10MG	N85009 001
/AB/		/25MG/	/N85108/001/
	a	25MG	N85108 001

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

/AA/	/BARR LABS/	/4MG/	/N80700/001/
	a BARR LABS	4MG	N80700 001

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL

>ADD >	AP	MARSAM PHARMS	25MG/ML¤	N89563 001	
>ADD >				APR 15, 1988	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLEOCIN HCL

>AOO >					
>ADD >		UPJOHN	EQ 300MG BASE¤	N50162 003	
>ADO >				APR 14, 1988	

CLINOAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

>ADD >	AP	ELKINS SINN	EQ 150MG BASE/ML¤	N62953 001	
>ADD >				APR 21, 1988	
>ADO >	AP	LEOERLE PARNTLS	EQ 150MG BASE/ML¤	N62889 001	
>ADO >				APR 25, 1988	
	AP	QUAD PHARMS	EQ 150MG BASE/ML¤	N62877 001	
				MAR 15, 1988	
	AP	SOLOPAK LABS	EQ 150MG BASE/ML¤	N62819 001	
				MAR 15, 1988	
	AP		EQ 150MG BASE/ML¤	N62852 001	
				MAR 17, 1988	

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

>ADO >	AB	LEOERLE LABS	0.1MG¤	N71783 001	
>ADD >				APR 05, 1988	
>ADD >	AB		0.2MG¤	N71784 001	
>ADD >				APR 05, 1988	
>ADD >	AB		0.3MG¤	N71785 001	
>ADD >				APR 05, 1988	

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

	AB	CHELSEA LABS	3.75MG¤	N71878 001	
				MAR 15, 1988	
	AB		7.5MG¤	N71879 001	
				MAR 15, 1988	
	AB		15MG¤	N71860 001	
				MAR 15, 1988	
>ADD >	AB	PUREPAC PHARM	3.75MG¤	N71924 001	
>ADD >				APR 25, 1988	
>ADD >	AB		7.5MG¤	N71925 001	
>ADD >				APR 25, 1988	
>ADD >	AB		15MG¤	N71926 001	
>ADD >				APR 25, 1988	
	AB	WARNER CHILCOTT	3.75MG¤	N71774 001	
				MAR 01, 1988	
	AB		7.5MG¤	N71775 001	
				MAR 01, 1988	
	AB		15MG¤	N71776 001	
				MAR 01, 1988	

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

	AB	WARNER CHILCOTT	3.75MG¤	N71828 001	
				MAR 03, 1988	
	AB		7.5MG¤	N71829 001	
				MAR 03, 1988	
	AB		15MG¤	N71830 001	
				MAR 03, 1988	
	AB	WATSON LABS	3.75MG¤	N71852 001	
				FEB 09, 1988	
	AB		7.5MG¤	N71853 001	
				FEB 09, 1988	
	AB		15MG¤	N71854 001	
				FEB 09, 1988	
>ADD >		**GEN-XENE**			
>ADD >	AB	ALRA LABS	3.75MG¤	N71787 001	
>ADD >				APR 26, 1988	
>ADD >	AB		7.5MG¤	N71788 001	
>ADD >				APR 26, 1988	
>ADD >	AB		15MG¤	N71789 001	
>ADD >				APR 26, 1988	

CLOXACILLIN SODIUM

POWDER FOR RECONSTITUTION; ORAL
CLOXACILLIN SODIUM

>ADD >	AA	BIOCRAFT LABS	EQ 125MG BASE/5ML	N62268 001	
>DLT >/	AB/		/EQ 125MG BASE/5ML/	/N62268/001/	

CLOXACILLIN SODIUM

POWDER FOR RECONSTITUTION; ORAL
TEGOPEN

> ADD >	AA	BRISTOL LABS	EQ 125MG BASE/5ML	N50192 001
> ADD >	AA		EQ 125MG BASE/5ML	N61453 001
> DLT >/	AB/		/EQ 125MG BASE/5ML/	/N50192/001/
> DLT >/	AB/		/EQ 125MG BASE/5ML/	/N61453/001/

COLCHICINE; PROBENECID

TABLET; ORAL
PROBENECID AND COLCHICINE

/BP/	/BEECHAM/LABS/	/0.5MG;500MG/	/N84321/001/
	BEECHAM LABS	0.5MG;500MG	N84321 001

PROBENECID W/ COLCHICINE

/BP/	/LEDERLE/LABS/	/0.5MG;500MG/	/N86954/001/
	LEDERLE LABS	0.5MG;500MG	N86954 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL

AB	DANBURY PHARMA	10MG		N71611 001
			MAY 03, 1989 :	FEB 29, 1988

FLEXERIL

AB	MS&D	10MG	N17821 002

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL

AB	VITARINE	10MG		N72167 001
				FEB 03, 1988
AB		150MG		N72254 001
				FEB 03, 1988

NORPRAMIN

AB	MERRELL DOW	10MG		N14399 007
				FEB 11, 1982
AB		150MG		N14399 006

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE

/BP/	/BARR/LABS/	/0.25MG/	/N84013/001/
	BARR LABS	0.25MG	N84013 001
/BP/		/0.25MG/	/N84764/001/
		0.25MG	N84764 001
/BP/		/0.5MG/	/N84084/001/
		0.5MG	N84084 001
/BP/		/0.75MG/	/N84081/001/
		0.75MG	N84081 001
/BP/		/0.75MG/	/N84765/001/
		0.75MG	N84765 001
/BP/		/1.5MG/	/N84086/001/
		1.5MG	N84086 001
/BP/		/1.5MG/	/N84763/001/
		1.5MG	N84763 001

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	10GM/100ML		N19626 004
				FEB 02, 1988

DEXTROSE 2.5% IN PLASTIC CONTAINER

	KENDALL MCGAW	2.5GM/100ML	N19626 001
			FEB 02, 1988

DEXTROSE 5% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	5GM/100ML		N19626 002
				FEB 02, 1988

DEXTROSE 7.7% IN PLASTIC CONTAINER

	KENDALL MCGAW	7.7GM/100ML		N19626 003
				FEB 02, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% W/ POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

/ABBOTT/LABS/	/5GM/100ML;74.5MG/100ML;/ 300MG/100ML/	/N18876/001/ /JAN/17,/1986/

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% W/ POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

//ABBOTT/LABS/	/5GM/100ML;149MG/100ML;/ 300MG/100ML/	/N18876/002/ /JAN/17,/1986/

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

/DEXTROSE/5%/AND/SODIUM/CHLORIDE/0.3%/W//POTASSIUM/CHLORIDE/
/0.224%/IN/PLASTIC/CONTAINER/
//ABBOTT/LABS/ /5GM/100ML;224MG/100ML;/
/300MG/100ML/ /N18876/001/
/JAN/17,/1986/

/DEXTROSE/5%;/SODIUM/CHLORIDE/0.225%;/POTASSIUM/CHLORIDE/
/0.15%/IN/PLASTIC/CONTAINER/
//ABBOTT/LABS/ /5GM/100ML;150MG/100ML;/
/225MG/100ML/ /N18365/001/

/DEXTROSE 5%; SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE/
/0.224% IN PLASTIC CONTAINER/
/AP/ //ABBOTT/LABS/ /5GM/100ML;224MG/100ML;/
/450MG/100ML/ /N18362/002/

/DEXTROSE 5%; SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE/
/0.3% IN PLASTIC CONTAINER/
/AP/ //ABBOTT/LABS/ /5GM/100ML;298MG/100ML;/
/450MG/100ML/ /N18362/003/

POTASSIUM CHLDRIDE 0.037% IN DEXTROSE 10% AND SODIUM
CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;37MG/10DML;
200MG/100ML¤ N19630 031
FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM
CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;37MG/100ML;
450MG/100ML¤ N19630 037
FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM
CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;37MG/100ML;
900MG/100ML¤ N19630 043
FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;37MG/100ML;
110MG/100ML¤ N19630 001
FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;37MG/100ML;
200MG/100ML¤ N19630 007
FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.33% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;37MG/100ML;
330MG/100ML¤ N19630 013
FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;37MG/100ML;
450MG/100ML¤ N19630 019
FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;37MG/100ML;
900MG/100ML¤ N19630 025
FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM
CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;75MG/100ML;
200MG/100ML¤ N19630 032
FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM
CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;75MG/100ML;
450MG/100ML¤ N19630 038
FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM
CHLORIDE D.9% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/10DML;75MG/100ML;
900MG/100ML¤ N19630 044
FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;75MG/100ML;
200MG/100ML¤ N19630 008
FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;75MG/100ML;
330MG/100ML¤ N19630 014
FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IH DEXTROSE 5% AND SODIUM CHLORIDE D.45% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;75MG/100ML;
450MG/100ML¤ N19630 020
FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;75MG/100ML;
900MG/100ML¤ N19630 026
FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;75MG/100ML;
110MG/100ML¤ N19630 002
FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;110MG/100ML; 200MG/100ML¤ N19630 033 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;110MG/100ML; 450MG/100ML¤ N19630 039 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;110MG/100ML; 900MG/100ML¤ N19630 045 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;110MG/100ML; 110MG/100ML¤ N19630 003 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;110MG/100ML; 200MG/100ML¤ N19630 009 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;110MG/100ML; 330MG/100ML¤ N19630 015 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;110MG/100ML; 450MG/100ML¤ N19630 021 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;110MG/100ML; 900MG/100ML¤ N19630 027 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;150MG/100ML; 200MG/100ML¤ N19630 034 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;150MG/100ML; 450MG/100ML¤ N19630 040 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;150MG/100ML; 900MG/100ML¤ N19630 046 FEB 17, 1988

AP **POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER**
KENDALL MCGAW 5GM/100ML;150MG/100ML; 200MG/100ML¤ N19630 010 FEB 17, 1988

AP **POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER**
KENDALL MCGAW 5GM/100ML;150MG/100ML; 330MG/100ML¤ N19630 016 FEB 17, 1988

AP **POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER**
KENDALL MCGAW 5GM/100ML;150MG/100ML; 450MG/100ML¤ N19630 022 FEB 17, 1988

AP **POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**
KENDALL MCGAW 5GM/100ML;150MG/100ML; 900MG/100ML¤ N19630 028 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;150MG/100ML; 110MG/100ML¤ N19630 004 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;220MG/100ML; 200MG/100ML¤ N19630 035 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;220MG/100ML; 450MG/100ML¤ N19630 041 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;220MG/100ML; 900MG/100ML¤ N19630 047 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;220MG/100ML; 110MG/100ML¤ N19630 005 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;220MG/100ML; 200MG/100ML¤ N19630 011 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;220MG/100ML; 330MG/100ML¤ N19630 017 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;220MG/100ML; 450MG/100ML¤ N19630 023 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;220MG/100ML; 900MG/100ML¤ N19630 029 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;300MG/100ML; 200MG/100ML¤ N19630 036 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;300MG/100ML; 450MG/100ML¤ N19630 042 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;300MG/100ML; 900MG/100ML¤ N19630 048 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;300MG/100ML; 200MG/100ML¤ N19630 012 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;300MG/100ML; 330MG/100ML¤ N19630 018 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;300MG/100ML; 450MG/100ML¤ N19630 024 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;300MG/100ML; 900MG/100ML¤ N19630 030 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;300MG/100ML; 110MG/100ML¤ N19630 006 FEB 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP ABBOTT LABS 5GM/100ML;74.5MG/100ML; 450MG/100ML¤ N18362 009 JUL 05, 1983
AP 5GM/100ML;149MG/100ML; 450MG/100ML¤ N18362 005 MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP ABBOTT LABS 5GM/100ML;74.5MG/100ML; 900MG/100ML¤ N19691 002 MAR 24, 1988
AP 5GM/100ML;149MG/100ML; 900MG/100ML¤ N19691 004 MAR 24, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
ABBOTT LABS 5GM/100ML;74.5MG/100ML; 225MG/100ML¤ N18365 002 JUL 05, 1983
5GM/100ML;149MG/100ML; 225MG/100ML¤ N18365 006 MAR 28, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;74.5MG/100ML; 300MG/100ML	N18876 001	JAN 17, 1986
		5GM/100ML;149MG/100ML; 300MG/100ML¤	N18876 006	MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	TRAVENOL LABS	5GM/100ML;75MG/100ML; 900MG/100ML¤	N19308 004	APR 05, 1985

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;224MG/100ML; 450MG/100ML¤	N18362 006	MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;224MG/100ML; 900MG/100ML¤	N19691 006	MAR 24, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;224MG/100ML; 225MG/100ML¤	N18365 008	MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;224MG/100ML; 300MG/100ML¤	N18876 007	MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;149MG/100ML; 450MG/100ML¤	N18362 010	JUL 05, 1983
AP		5GM/100ML;298MG/100ML; 450MG/100ML¤	N18362 007	MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;149MG/100ML; 900MG/100ML¤	N19691 005	MAR 24, 1988
AP		5GM/100ML;298MG/100ML; 900MG/100ML¤	N19691 008	MAR 24, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;149MG/100ML; 225MG/100ML	N18365 001	JAN 17, 1986
		5GM/100ML;298MG/100ML; 225MG/100ML¤	N18365 009	MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;149MG/100ML; 300MG/100ML	N18876 002	JAN 17, 1986
		5GM/100ML;298MG/100ML; 300MG/100ML¤	N18876 008	MAR 28, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;224MG/100ML; 450MG/100ML	N18362 002	

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;224MG/100ML; 900MG/100ML¤	N19691 007	MAR 24, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;224MG/100ML; 225MG/100ML¤	N18365 003	JUL 05, 1983

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;224MG/100ML; 300MG/100ML	N18876 003	JAN 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	TRAVENOL LABS	5GM/100ML;224MG/100ML; 900MG/100ML¤	N19308 006	APR 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;298MG/100ML; 450MG/100ML	N18362 003	

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;298MG/100ML; 900MG/100ML¤	N19691 009	MAR 24, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 4DMEQ IN DEXTROSE 5% AND SOOIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
ABBOTT LABS 5GM/100ML;298MG/100ML; 225MG/100ML¤ N18365 004 JUL 05, 1983

POTASSIUM CHLORIDE 40MEQ IN OEXTROSE 5% AND SODIUM CHLORIDE D.3% IN PLASTIC CONTAINER
ABBOTT LABS 5GM/100ML;298MG/100ML; 300MG/100ML¤ N18876 004 MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;74.5MG/100ML; 450MG/100ML¤ N18362 008 MAR 28, 1988

AP 5GM/100ML;149MG/100ML; 450MG/100ML¤ N18362 004 MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;74.5MG/100ML; 900MG/100ML¤ N19691 001 MAR 24, 1988

AP 5GM/100ML;149MG/100ML; 900MG/100ML¤ N19691 003 MAR 24, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
ABBOTT LABS 5GM/100ML;74.5MG/100ML; 225MG/100ML¤ N18365 D05 MAR 28, 1988

5GM/100ML;149MG/100ML; 225MG/100ML¤ N18365 007 MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ABBOTT LABS 5GM/100ML;74.5MG/100ML; 300MG/100ML¤ N18876 D05 MAR 28, 1988

5GM/10DML;149MG/100ML; 300MG/100ML¤ N18876 009 MAR 28, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

OEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;110MG/100ML¤ N19631 011 FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;200MG/100ML¤ N19631 012 FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;330MG/100ML# N19631 013 FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;450MG/100ML# N19631 014 FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP KENDALL MCGAW 10GM/100ML;900MG/100ML¤ N19631 015 FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 2.5GM/100ML; 110MG/100ML¤ N19631 001 FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 2.5GM/100ML; 2D0MG/1D0ML¤ N19631 002 FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
KENDALL MCGAW 2.5GM/100ML; 330MG/100ML¤ N19631 003 FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP KENDALL MCGAW 2.5GM/100ML; 450MG/100ML¤ N19631 004 FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE D.9% IN PLASTIC CONTAINER
KENDALL MCGAW 2.5GM/100ML; 900MG/100ML¤ N19631 005 FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;110MG/100ML¤ N19631 006 FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;200MG/100ML¤ N19631 007 FEB 24, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	5GM/100ML;330MG/100ML¤	N19631 008	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	5GM/100ML;450MG/100ML¤	N19631 009	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	5GM/100ML;900MG/100ML¤	N19631 010	FEB 24, 1988

DIAZEPAM

TABLET; ORAL

Q-PAM

>ADD >	AB	QUANTUM PHARMCS	2MG¤	N72431 001	APR 29, 1988
>ADD >	AB		5MG¤	N72432 001	APR 29, 1988
>ADD >	AB		10MG¤	N72433 001	APR 29, 1988

DIAZOXIDE

INJECTABLE; INJECTION

DIAZOXIDE

AP	QUAD PHARMS	15MG/ML¤	N71908 001	JAN 26, 1988

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

>ADD >	AP	BAXTER	80MG/100ML	N19615 001	MAR 27, 1987
>ADD >	AP		160MG/100ML	N19615 002	MAR 27, 1987
>ADD >	AP		320MG/100ML	N19615 003	MAR 27, 1987
>ADD >			640MG/100ML	N19615 004	MAR 27, 1987
>DLT >	/AP/	/TRAVENOL LABS/	/80MG/100ML/	/N19615/001/	/MAR/27,/1987/
>DLT >	/AP/		/160MG/100ML/	/N19615/002/	/MAR/27,/1987/
>DLT >	/AP/		/320MG/100ML/	/N19615/003/	/MAR/27,/1987/
>DLT >			/640MG/100ML/	/N19615/004/	/MAR/27,/1987/

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

ADAPIN

>ADD >	AB	PENNWALT	EQ 15MG BASE	N16987 007	APR 13, 1987

DOXEPIN HCL

AB	BARR LABS	EQ 25MG BASE¤	N71502 001	FEB 18, 1988
AB		EQ 50MG BASE¤	N71653 001	FEB 18, 1988
AB		EQ 75MG BASE¤	N71654 001	FEB 18, 1988
AB		EQ 100MG BASE¤	N71521 001	FEB 18, 1988
AB	CHELSEA LABS	EQ 75MG BASE¤	N71763 001	FEB 09, 1988
AB		EQ 150MG BASE¤	N71764 001	FEB 09, 1988
AB	LEDERLE LABS	EQ 10MG BASE¤	N71685 001	JAN 05, 1988
AB		EQ 25MG BASE¤	N71686 001	JAN 05, 1988
AB		EQ 50MG BASE¤	N71673 001	JAN 05, 1988
AB		EQ 75MG BASE¤	N71674 001	JAN 05, 1988
AB		EQ 100MG BASE¤	N71675 001	JAN 05, 1988
AB		EQ 150MG BASE¤	N71676 001	JAN 05, 1988

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE
> ADD > AB VITARINE EQ 50MG BASE¤ N62780 001 APR 12, 1988

INJECTABLE; INJECTION
DOXYCYCLINE
AP BEN VENUE LABS EQ 100MG BASE/VIAL¤ N62569 001 MAR 09, 1988
AP EQ 200MG BASE/VIAL¤ N62569 002 MAR 09, 1988

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL
AP ABBOTT LABS 2.5MG/ML¤ N71981 001 FEB 29, 1988
> ADD > AP DUPONT CRI CARE 2.5MG/ML¤ N71645 001 APR 07, 1988

ENALAPRILAT

INJECTABLE; INJECTION
VASOTEC
MS&D RES LABS 1.25MG/ML¤ N19309 001 FEB 09, 1988

ERGOLOID MESYLATES

TABLET; SUBLINGUAL
CIRCANOL
> DLT >/AA/ /RIKER/LABS/ /0.5MG/ /N84868/001/
> DLT >/AA/ /1MG/ /N85809/001/
> ADD > ∂ 0.5MG N84868 001
> ADD > ∂ 1MG N85809 001

ERYTHROMYCIN

SOLUTION; TOPICAL
ETS-2%
AT PADDOCK LABS 2%¤ N62687 001 FEB 05, 1988

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROCIN
AP ABBOTT LABS EQ 500MG BASE/VIAL¤ N62586 001 JAN 04, 1988
AP EQ 1GM BASE/VIAL¤ N62586 002 JAN 04, 1988

ERYTHROMYCIN STEARATE

TABLET; ORAL
BRISTAMYCIN
/AB/ /BRISTOL/LABS/ /EQ 250MG BASE/ /N61304/001/
∂ BRISTOL LABS EQ 250MG BASE N61304 001
/AB/ /EQ 250MG BASE/ /N61887/001/
∂ EQ 250MG BASE N61887 001
ERYPAR
/AB/ /PARKE/DAVIS/ /EQ 250MG BASE/ /N62032/001/
∂ PARKE DAVIS EQ 250MG BASE N62032 001
/AB/ /EQ 500MG BASE/ /N62032/002/
∂ EQ 500MG BASE N62032 002
ERYTHROCIN STEARATE
/AB/ /ABBOTT/LABS/ /EQ 125MG BASE/ /N60359/002/
∂ ABBOTT LABS EQ 125MG BASE N60359 002
ERYTHROMYCIN STEARATE
/AB/ /LEDERLE/LABS/ /EQ 250MG BASE/ /N62089/001/
∂ LEDERLE LABS EQ 250MG BASE N62089 001
/AB/ /EQ 500MG BASE/ /N62089/002/
∂ EQ 500MG BASE N62089 002
PFIZER-E
/AB/ /PFIZER/LABS/ /EQ 500MG BASE/ /N61791/002/
∂ PFIZER LABS EQ 500MG BASE N61791 002

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
> ADD > NORETHIN 1/35E-21
> ADD > AB SEARLE PHARMS 0.035MG;1MG¤ N71480 001 APR 12, 1988
> ADD > NORETHINDRONE AND ETHINYL ESTRADIOL
> ADD > AB WATSON LABS 0.035MG;0.5MG AND 1MG¤ N71043 001 APR 01, 1988

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

ORTHO-NOVUM 10/11-21

> ADD > AB ORTHO PHARM 0.035MG;0.5MG AND 1MG N18354 001
> ADD > JAN 11, 1982

TABLET; ORAL-28

> ADD > NORETHIN 1/35E-28

> ADD > AB SEARLE PHARMS 0.035MG;1MG¤ N71481 001
> ADD > APR 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

> ADD > AB WATSON LABS 0.035MG;0.5MG AND 1MG¤ N71044 001
> ADD > APR 01, 1988

ORTHO-NOVUM 10/11-28

> ADD > AB ORTHO PHARM 0.035MG;0.5MG AND 1MG N18354 002
> ADD > JAN 11, 1982

FENOPROFEN CALCIUM

CAPSULE; ORAL

> ADD > FENOPROFEN CALCIUM

> ADD > AB QUANTUM PHARMCS EQ 200MG BASE¤ N72214 001
> ADD > AUG 17, 1988 : APR 14, 1988
> ADD > AB EQ 300MG BASE¤ N71738 001
> AOD > AUG 17, 1988 : APR 14, 1988

NALFON

> ADD > AB DISTA PRODS EQ 300MG BASE N17604 002

NALFON 200

> ADD > AB DISTA PRODS EQ 200MG BASE N17604 003

TABLET; ORAL

> ADD > FENOPROFEN CALCIUM

> ADD > AB LEDERLE LABS EQ 600MG BASE¤ N72326 001
> ADD > AUG 17, 1988 : APR 20, 1988
> ADD > AB QUANTUM PHARMCS EQ 600MG BASE¤ N72194 001
> AOD > AUG 17, 1988 : APR 14, 1988

NALFON

> ADD > AB DISTA PRODS EQ 600MG BASE N17710 001

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

DERMA-SMOOTHE/FS

HILL DERM 0.01%¤ N19452 001
FEB 03, 1988

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

> ADD > AB CLAY PARK LABS 0.05%¤ N71790 001
> ADD > JUL 13, 1988 : APR 25, 1988

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP BEN VENUE LABS 50MG/ML¤ N89508 001
JAN 26, 1988

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

PERMITIL

/S/ SCHERING /2.5MG/ /N12034/004/

BP SCHERING 2.5MG N12034 004

/S/ /5MG/ /N12034/005/

BP 5MG N12034 005

/S/ /10MG/ /N12034/006/

BP 10MG N12034 006

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HCL

AB HALSEY DRUG 15MG¤ N71808 001
JAN 07, 1988

AB 30MG¤ N71809 001
JAN 07, 1988

FOLIC ACID

TABLET; ORAL

FOLIC ACID

/AA/ /BARR LABS/ /1MG/ /N89177/001/
/JAN 08, 1986/

∂ BARR LABS 1MG N89177 001
JAN 08, 1986

FUROSEMIDE

INJECTABLE; INJECTION

	FUROSEMIDE		
/AP/	/PARKE/DAVIS/	/10MG/ML/	/N18420/001/ /FEB/26,/1982/
AP	WARNER CHILCOTT	10MG/ML	N18420 001 FEB 26, 1982

TABLET; ORAL

	FUROSEMIDE		
AB	BARR LABS	80MG	N70100 001 JAN 26, 1988
AB	OANBURY PHARMA	80MG	N71594 001 FEB 09, 1988

HALOPERIDOL

TABLET; ORAL

	HALDOL SOLUTAB		
/A/	/MCNEIL/LABS/	/1MG/	/N17079/001/
	∂ MCNEIL PHARM	1MG	N17079 001
	HALOPERIDOL		
AB	BARR LABS	5MG	N71212 001 JAN 07, 1988
AB		10MG	N71173 001 JAN 07, 1988
AB		20MG	N71177 001 JAN 07, 1988
AB	CORD LABS	10MG	N71210 001 MAR 11, 1988
AB		20MG	N71211 001 MAR 11, 1988

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

	HALDOL		
/AA/	/MCNEIL/LABS/	/EQ 2MG BASE/ML/	/N15922/001/
AA	MCNEIL PHARM	EQ 2MG BASE/ML	N15922 001
> ADD >	**HALOPERIDOL INTENSOL**		
> ADD > AA	ROXANE LABS	EQ 2MG BASE/ML	N72045 001 APR 12, 1988
> ADD >			

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

> OLT >/AP/	/ABBOTT/LABS/	/10,000 UNITS/100ML/	/N19339/003/ /MAR/27,/1985/
> DLT >			
> ADD >	∂ ABBOTT LABS	10,000 UNITS/100ML	N19339 003 MAR 27, 1985
> ADD >			

HEPARIN SODIUM 1000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

> ADD > AP	BAXTER	200 UNITS/100ML	N18609 001 APR 28, 1982
> ADD >			
> DLT >/AP/	/TRAVENOL/LABS/	/200 UNITS/100ML/	/N18609/001/ /APR/28,/1982/
> DLT >			

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

> DLT >/AP/	/ABBOTT/LABS/	/5,000 UNITS/100ML/	/N19339/001/ /MAR/27,/1985/
> OLT >			
> ADD >	∂ ABBOTT LABS	5,000 UNITS/100ML	N19339 001 MAR 27, 1985
> ADD >			

HEPARIN SODIUM 2000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

> ADD > AP	BAXTER	200 UNITS/100ML	N18609 002 APR 28, 1982
> ADD >			
> DLT >	/HEPARIN SODIUM 20000 UNITS AND SODIUM CHLORIDE 0.9% IN/		
> DLT >	/PLASTIC CONTAINER/		
> DLT >/AP/	/TRAVENOL/LABS/	/200 UNITS/100ML/	/N18609/002/ /APR/28,/1982/
> DLT >			

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

> DLT >/AP/	/ABBOTT/LABS/	/5,000 UNITS/100ML/	/N19339/004/ /MAR/27,/1985/
> DLT >			
> DLT >/AP/		/10,000 UNITS/100ML/	/N19339/002/ /MAR/27,/1985/
> DLT >			
> ADD >	∂	5,000 UNITS/100ML	N19339 004 MAR 27, 1985
> ADD >			
> ADD >	∂	10,000 UNITS/100ML	N19339 002 MAR 27, 1985
> ADD >			

HEPARIN SODIUM 5000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

> ADD > AP	BAXTER	500 UNITS/100ML	N18609 003 APR 28, 1982
> ADD >			
> DLT >/AP/	/TRAVENOL/LABS/	/500 UNITS/100ML/	/N18609/003/ /APR/28,/1982/
> DLT >			

HYORALAZINE HYDROCHLORIDE

TABLET; ORAL

	HYDRALAZINE HCL		
/AA/	/PUREPAC/PHARM/	/50MG/	/N88178/001/ /AUG/15,/1983/
	∂ PUREPAC PHARM	50MG	N88178 001 AUG 15, 1983

HYDROCHLOROTHIAZIDE

TABLET; ORAL

	HYDROCHLOROTHIAZIDE			
/AB/	/BANMAX/PHARMS/	/25MG/	/N86369/001/	
	BANMAX PHARMS	25MG	N86369 001	
/AB/		/50MG/	/N83554/001/	
	∂	50MG	N83554 001	

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

	NORMOZIDE			
> DLT > /AB/	/SCHERING/	/25MG;400MG/	/N19046/004/	
> DLT >			/APR/06,/1987/	
> ADD >	∂ SCHERING	25MG;400MG	N19046 004	
> ADD >			APR 06, 1987	
> ADD >	TRANDATE HCT			
> ADD > AB	GLAXO	25MG;100MG	N19174 001	
> ADD >			APR 10, 1987	
> ADD > AB		25MG;200MG	N19174 002	
> ADD >			APR 10, 1987	
> ADD > AB		25MG;300MG	N19174 003	
> ADD >			APR 10, 1987	
> ADD >	∂	25MG;400MG	N19174 004	
> ADD >			APR 10, 1987	
> DLT >	/TRANDATE-HCT/			
> DLT > /AB/	/GLAXO/	/25MG;100MG/	/N19174/001/	
> DLT >			/APR/10,/1987/	
> DLT > /AB/		/25MG;200MG/	/N19174/002/	
> DLT >			/APR/10,/1987/	
> DLT > /AB/		/25MG;300MG/	/N19174/003/	
> DLT >			/APR/10,/1987/	
> DLT > /AB/		/25MG;400MG/	/N19174/004/	
> DLT >			/APR/10,/1987/	

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

	METHYLDOPA AND HYDROCHLOROTHIAZIDE			
> ADD > AB	NOVOPHARM	15MG;250MG¤	N71819 001	
> ADD >			APR 08, 1988	
> ADD > AB		25MG;250MG¤	N71820 001	
> ADD >			APR 08, 1988	
> ADD > AB		30MG;500MG¤	N71821 001	
> ADD >			APR 08, 1988	
> ADD > AB		50MG;500MG¤	N71822 001	
> ADD >			APR 08, 1988	
/AB/	/PUREPAC/PHARM/	/50MG;500MG/	/N70689/001/	
			/APR/24,/1986/	
	∂ PUREPAC PHARM	50MG;500MG	N70689 001	
			APR 24, 1986	

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

	METHYLDOPA AND HYDROCHLOROTHIAZIDE			
AB	ZENITH LABS	15MG;250MG¤	N71458 001	
			MAR 08, 1988	
AB		25MG;250MG¤	N71459 001	
			MAR 08, 1988	
AB		30MG;500MG¤	N71460 001	
			MAR 08, 1988	
AB		50MG;500MG¤	N71461 001	
			MAR 08, 1988	

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE			
AB	SIDMAK LABS	25MG;40MG¤	N72042 001	
			MAR 14, 1988	
AB		25MG;80MG¤	N72043 001	
			MAR 14, 1988	
AB	WARNER CHILCOTT	25MG;40MG¤	N71771 001	
			JAN 26, 1988	
AB		25MG;80MG¤	N71772 001	
			JAN 26, 1988	

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

	RESERPINE AND HYDROCHLOROTHIAZIDE			
/BP/	/BARR/LABS/	/25MG;0.125MG/	/N84580/001/	
	BARR LABS	25MG;0.125MG	N84580 001	
/BP/		/50MG;0.125MG/	/N84579/001/	
	∂	50MG;0.125MG	N84579 001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
AB	VITARINE	25MG;50MG¤	N71737 001	
			FEB 12, 1988	

TABLET; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
AB	DANBURY PHARMA	50MG;75MG¤	N71969 001	
			APR 17, 1988 : JAN 15, 1988	
AB	QUANTUM PHARMCS	50MG;75MG¤	N71980 001	
			APR 17, 1988 : FEB 01, 1988	

HYDROCORTISONE

CREAM; TOPICAL

		HYDROCORTISONE		
AT		NASKA PHARMA	1%	N89706 001 MAR 10, 1988
AT			2.5%	N89682 001 MAR 10, 1988
>ADD>		**HYDROTEX**		
>ADD> AT		SYOSSET LABS	1%	N87427 001 APR 04, 1988

LOTION; TOPICAL

		BETA-HC		
AT		BETA DERM	1%	N89495 001 JAN 25, 1988
		HYDROCORTISONE		
>ADD> AT		NASKA PHARMA	1%	N89705 001 APR 25, 1988

OINTMENT; TOPICAL

		HYDROCORTISONE		
AT		NASKA PHARMA	1%	N89704 001 MAR 10, 1988

TABLET; ORAL

		HYDROCORTISONE		
/BP/	/BARR/LABS/		/20MG/	/N83999/001/
BP	ə BARR LABS		20MG	N83999 001

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

		HYDROXYZINE HCL		
>DLT>/AP/		/ALTANA/	/25MG/ML/	/N87273/001/ /APR/20,/1982/
>DLT>				
>DLT>/AP/			/50MG/ML/	/N87273/002/ /APR/20,/1982/
>DLT>				
>ADD>		ə	25MG/ML	N87273 001 APR 20, 1982
>ADD>				
>ADD>		ə	50MG/ML	N87273 002 APR 20, 1982
>ADD>				

SYRUP; ORAL

		HYDROXYZINE HCL		
AA		NASKA PHARMA	10MG/5ML	N88785 001 FEB 03, 1988

IBUPROFEN

TABLET; ORAL

		IBUPROFEN		
AB		HALSEY DRUG	800MG	N72137 001 FEB 05, 1988
AB		INVAMED	400MG	N72064 001 JAN 14, 1988
AB			600MG	N72065 001 JAN 14, 1988
AB			800MG	N71938 001 JAN 14, 1988
AB		MEDICOPHARMA	400MG	N71644 001 FEB 01, 1988
AB		PUREPAC PHARM	800MG	N71964 001 FEB 01, 1988

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

		PRAMINE		
/AB/		/BANMAX/PHARMS/	/10MG/	/N83827/001/
		ə BANMAX PHARMS	10MG	N83827 001
/AB/			/25MG/	/N83827/002/
		ə	25MG	N83827 002
/BP/			/50MG/	/N83827/003/
		ə	50MG	N83827 003

INDOMETHACIN

CAPSULE; ORAL

		INDOMETHACIN		
>ADD> AB		NOVOPHARM	25MG	N71342 001 APR 18, 1988
>ADD>				
>ADD> AB			50MG	N71343 001 APR 18, 1988
>ADD>				

IOHEXOL

INJECTABLE; INJECTION

		OMNIPAQUE 180		
		/ə/STERLING/DRUG/	/38.8%/	/N18956/001/ /DEC/26,/1985/
AP		STERLING DRUG	38.8%	N18956 001 DEC 26, 1985

ISOSORBIDE DINITRATE

TABLET; ORAL
ISOSORBIDE DINITRATE

	AB	BARR LABS	30MG¤	N87564 001	SEP 18, 1986
	AB	CORD LABS	5MG¤	N86221 001	JAN 07, 1988
	AB		10MG¤	N86223 001	JAN 07, 1988
> ADD >	AB		20MG¤	N89367 001	APR 07, 1988
> ADD >					
	AB	DANBURY PHARMA	5MG¤	N86034 001	JAN 06, 1988
	AB		10MG¤	N86032 001	JAN 07, 1988
	AB	PAR PHARM	30MG¤	N87946 001	JAN 12, 1988

TABLET; SUBLINGUAL
ISOSORBIDE DINITRATE

	AB	CORD LABS	2.5MG¤	N86225 001	FEB 19, 1988
	AB		5MG¤	N86222 001	FEB 19, 1988
	AB	DANBURY PHARMA	2.5MG¤	N86033 001	FEB 26, 1988
	AB		5MG	N86031 001	SEP 29, 1987

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETALAR

> ADD >	AP	PARKE DAVIS	EQ 10MG BASE/ML	N16812 001	JUL 31, 1984
> ADD >	AP		EQ 50MG BASE/ML	N16812 002	
> ADD >	AP		EQ 100MG BASE/ML	N16812 003	
> ADD >		**KETAMINE HCL**			
> ADD >	AP	QUAD PHARMS	EQ 10MG BASE/ML¤	N71949 001	APR 11, 1988
> ADD >					
> ADD >	AP		EQ 50MG BASE/ML¤	N71950 001	APR 11, 1988
> ADD >					
> ADD >	AP		EQ 100MG BASE/ML¤	N71951 001	APR 11, 1988
> ADD >					

LACTULOSE

SYRUP; ORAL
LACTULOSE

> ADD >		@ KALI DUPHAR	10GM/15ML	N17906 001	
> DLT >	/AA/	/ROXANE/LABS/	/10GM/15ML/	/N17906/001/	

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

	AP	BEN VENUE LABS	EQ 100MG BASE/VIAL¤	N89717 001	MAR 28, 1988
	AP	QUAD PHARMS	EQ 100MG BASE/VIAL	N89636 001	DEC 24, 1987

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
POLOCAINE W/ LEVONORDEFRIN

> ADD >					
> ADD >	AP	ASTRA PHARM PRODS	0.05MG/ML;2%¤	N89517 001	APR 14, 1988
> ADD >					

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
LINCOCIN

	AP	UPJOHN	EQ 300MG BASE/ML	N50317 001	
		LINCOMYCIN HCL			
	AP	QUAD PHARMS	EQ 300MG BASE/ML¤	N62784 001	MAR 14, 1988

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
IMODIUM

> DLT >		JANSSEN/PHARMA/	/1MG/5ML/	/N19037/001/	
> DLT >				/JUL/31,/1984/	
> ADD >		@ JANSSEN PHARMA	1MG/5ML	N19037 001	
> ADD >				JUL 31, 1984	

LORAZEPAM

TABLET; ORAL
LORAZEPAM

> ADD >	AB	CORD LABS	0.5MG¤	N71193 001	APR 15, 1988
> ADD >					
> ADD >	AB		1MG¤	N71194 001	APR 15, 1988
> ADD >					
> ADD >	AB		2MG¤	N71195 001	APR 15, 1988
> ADD >					
	AB	WARNER CHILCOTT	1MG¤	N71038 001	JAN 12, 1988
	AB		2MG¤	N71039 001	JAN 12, 1988

MAPROTILINE HYDRDCHLORIDE

TABLET; ORAL

	MAPROTILINE HCL			
AB	AM THERPTCS	25MG¤	N72129 001	JAN 14, 1988
AB		50MG¤	N72130 001	JAN 14, 1988
AB		75MG¤	N72131 001	JAN 14, 1988

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

	ANTIVERT			
AA	ROERIG	50MG	N10721 001	JAN 20, 1982
	MECLIZINE HCL			
AA	PAR PHARM	50MG¤	N89674 001	MAR 31, 1988

MECLOFENAMATE SODIUM

CAPSULE; ORAL

	MECLOFENAMATE SODIUM			
AB	PAR PHARM	EQ 50MG BASE¤	N72077 001	MAR 10, 1988
AB		EQ 100MG BASE¤	N72078 001	MAR 10, 1988
AB	PHARM BASICS	EQ 50MG BASE¤	N71007 001	MAR 25, 1988
AB		EQ 100MG BASE¤	N71008 001	MAR 25, 1988

MEFENAMIC ACID

CAPSULE; ORAL

>ADD>	**MEFENAMIC ACID**			
>ADD> AB	VITARINE	250MG¤	N72179 001	APR 21, 1988
	PONSTEL			
>ADD> AB	PARKE DAVIS PR	250MG	N15034 003	

MESTRANOL; NORETNINDRONE

TABLET; ORAL-21

>ADD>	**NORETHIN 1/50M-21**			
>ADD> AB	SEARLE PHARMS	0.05MG;1MG¤	N71539 001	APR 12, 1988

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

>ADD>	**NORETHIN 1/50M-28**			
>ADD> AB	SEARLE PHARMS	0.05MG;1MG¤	N71540 001	APR 12, 1988

MESTRANOL; NORETHYNODREL

TABLET; ORAL-20

	ENOVID			
>DLT>/AB/	/SEARLE/	/0.075MG;5MG/	/N10976/004/	
>ADD>	@ SEARLE	0.075MG;5MG	N10976 004	
	ENOVID-E			
>DLT>/AB/	/SEARLE/	/0.1MG;2.5MG/	/N10976/006/	
>ADD>	@ SEARLE	0.1MG;2.5MG	N10976 006	

METAPROTERENOL SULFATE

TABLET; ORAL

	ALUPENT			
AB	BOEHR INGEL	10MG	N15874 002	
AB		20MG	N15874 001	
	METAPROTERENOL SULFATE			
AB	PHARM BASICS	10MG¤	N71013 001	JAN 25, 1988
AB		20MG¤	N71014 001	JAN 25, 1988

METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL			
/AA/	/BARR/LABS/	/500MG/	/N84488/001/	
	@ BARR LABS	500MG	N84488 001	

METHOTREXATE SODIUM

INJECTABLE; INJECTION

	METHOTREXATE			
>ADD>	LEDERLE LABS	EQ 1GM BASE/VIAL¤	N11719 009	APR 07, 1988

METHOXSALEN

CAPSULE; ORAL

	OXSORALEN			
	/ELDER/PHARMS/	/10MG/	/N09648/001/	

METHOXSALEN

CAPSULE; ORAL
8-MOP
ELDER PHARMS 10MG N09048 001

METHYLDOPA

TABLET; ORAL
METHYLDOPA
AB CORD LABS 125MG¤ N71700 001 MAR 02, 1988
AB HALSEY DRUG 125MG¤ N71751 001 MAR 28, 1988
AB 250MG¤ N71752 001 MAR 28, 1988
AB 500MG¤ N71753 001 MAR 28, 1988

METHYLPREDNISOLONE

TABLET; ORAL
MEDROL
>ADD > AB UPJOHN 24MG N11153 005
>ADD > AB 32MG N11153 006
METHYLPREDNISOLONE
>ADD > AB PAR PHARM 16MG¤ N89207 001 APR 25, 1988
>ADD > AB 24MG¤ N89208 001 APR 25, 1988
>ADD > AB 32MG¤ N89209 001 APR 25, 1988

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL
AB SIDMAK LABS EQ 10MG BASE¤ N71250 001 FEB 03, 1988

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION
MEZLIN
MILES PHARM EQ 20GM BASE/VIAL¤ N50549 005 MAR 02, 1988
EQ 20GM BASE/VIAL¤ N62372 004 MAR 02, 1988

MITOMYCIN

INJECTABLE; INJECTION
MUTAMYCIN
BRISTOL MYERS 40MG/VIAL¤ N62336 003 MAR 10, 1988

MORPHINE SULFATE

TABLET, CONTROLLED RELEASE; ORAL
MS CONTIN
>ADD > PURDUE FRDRK 60MG¤ N19516 002 APR 08, 1988

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIN
HERBERT LABS 1%¤ N19599 001 FEB 29, 1988

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL
AP INTL MEDTN SYS 1MG/ML¤ N72076 001 MAR 24, 1988
>ADD > AP 1MG/ML¤ N72115 001 APR 27, 1988

>ADD > NIZATIDINE

>ADD > CAPSULE; ORAL
>ADD > AXID
>ADD > LILLY 150MG¤ N19508 001 APR 12, 1988
>ADD > 300MG¤ N19508 002 APR 12, 1988

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
AVENTYL HCL
8D LILLY EQ 10MG BASE N14684 001
8D EQ 25MG BASE N14684 002
/BP/ /EQ 10MG BASE/ /N14684/001/
/BP/ /EQ 25MG BASE/ /N14684/002/

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
PAMELOR

BD	SANDOZ PHARMS	EQ 10MG BASE	N18013 001	
BD		EQ 25MG BASE	N18013 002	
/BP/		/EQ/10MG/BASE/	/N18013/001/	
/BP/		/EQ/25MG/BASE/	/N18013/002/	

NYSTATIN

SUSPENSION; ORAL
NYSTATIN

AA	THAMES PHARMA	100,000 UNITS/ML	N62876 001 FEB 29, 1988

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

AB	AM THERPTCS	10MG	N71955 001 MAR 03, 1988
AB		15MG	N71956 001 MAR 03, 1988
AB		30MG	N71957 001 MAR 03, 1988
AB	CHELSEA LABS	10MG	N71661 001 MAR 02, 1988
AB		15MG	N71662 001 MAR 02, 1988
AB		30MG	N71663 001 MAR 02, 1988
>ADD> AB	CORD LABS	10MG	N71813 001 APR 19, 1988
>ADD> AB		15MG	N71756 001 APR 19, 1988
>ADD> AB		30MG	N71814 001 APR 19, 1988
>DLT> /BP/	/HYLAN/PHARMS/	/10MG/	/N71713/001/ /OCT/20,/1987/
>DLT> /BP/		/15MG/	/N71714/001/ /OCT/20,/1987/
>DLT> /BP/		/30MG/	/N71715/001/ /OCT/20,/1987/
>ADD> a		10MG	N71713 001 OCT 20, 1987
>ADD> a		15MG	N71714 001 OCT 20, 1987
>ADD> a		30MG	N71715 001 OCT 20, 1987

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

>ADD> AB	PUREPAC PHARM	10MG	N72251 001 APR 14, 1988
>ADD> AB		15MG	N72252 001 APR 14, 1988
>ADD> AB		30MG	N72253 001 APR 14, 1988

SERAX

AB	WYETH	10MG	N15539 002
AB		15MG	N15539 004
AB		30MG	N15539 006
/BP/		/10MG/	/N15539/002/
/BP/		/15MG/	/N15539/004/
/BP/		/30MG/	/N15539/006/

ZAXOPAM

AB	QUANTUM PHARMCS	10MG	N70650 001 MAR 01, 1988
AB		15MG	N70640 001 MAR 01, 1988
AB		30MG	N70641 001 MAR 01, 1988

OXYBUTYNIN CHLORIDE

TABLET; ORAL
DITROPAN

AB	MARION LABS	5MG	N17577 001

OXYBUTYNIN CHLORIDE

AB	PHARM BASICS	5MG	N70746 001 MAR 10, 1988

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
OXYTETRACYCLINE HCL

/AB/	/PUREPAC/PHARM/	/EQ 250MG BASE/	/N60634/001/
a	PUREPAC PHARM	EQ 250MG BASE	N60634 001

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

	PANCURONIUM				
AP	ELKINS SINN	1MG/ML¤	N72058 001	> DLT >	
			MAR 23, 1988	> ADD >	
AP		2MG/ML¤	N72059 001		
			MAR 23, 1988		
AP		2MG/ML¤	N72060 001		
			MAR 23, 1988		
	PANCURONIUM BROMIDE				
AP	ASTRA PHARM PRODS	1MG/ML¤	N72210 001		
			MAR 31, 1988		
AP		2MG/ML¤	N72211 001		
			MAR 31, 1988		
AP		2MG/ML¤	N72212 001		
			MAR 31, 1988		
AP		2MG/ML¤	N72213 001		
			MAR 31, 1988		
	PAVULON				
AP	ORGANON	1MG/ML	N17015 002		
AP		2MG/ML	N17015 001		

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

PENICILLIN G POTASSIUM			
/AA/	/PUREPAC/PHARM/	/400,000 UNITS/5ML/	/N61740/002/
ə	PUREPAC PHARM	400,000 UNITS/5ML	N61740 002

TABLET; ORAL

PENICILLIN G POTASSIUM			
/AB/	/PUREPAC/PHARM/	/250,000 UNITS/	/N61588/002/
ə	PUREPAC PHARM	250,000 UNITS	N61588 002
/AB/		/400,000 UNITS/	/N61588/003/
ə		400,000 UNITS	N61588 003

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

PENICILLIN V POTASSIUM				> ADD >	
/AA/	/PUREPAC/PHARM/	/EQ 250MG BASE/5ML/	/N61758/002/	> ADD >	AA
ə	PUREPAC PHARM	EQ 250MG BASE/5ML	N61758 002	> ADD >	
				> ADD >	
				> ADD >	

TABLET; ORAL

PENICILLIN V POTASSIUM					
/AB/	/PUREPAC/PHARM/	/EQ 250MG BASE/	/N61571/002/	> ADD >	AA
ə	PUREPAC PHARM	EQ 250MG BASE	N61571 002	> ADD >	
/AB/		/EQ 500MG BASE/	/N61571/003/	> ADD >	
ə		EQ 500MG BASE	N61571 003	> ADD >	

PERPHENAZINE

SYRUP; ORAL

	TRILAFON				
	SCHERING/	/2MG/5ML/	/N11294/002/		
ə	SCHERING	2MG/5ML	N11294 002		

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE			
/AA/	/BARR LABS/	/35MG/	/N83644/001/
ə	BARR LABS	35MG	N83644 001
/AA/		/35MG/	/N83684/001/
ə		35MG	N83684 001
/AA/		/35MG/	/N83686/001/
ə		35MG	N83686 001
/AA/		/35MG/	/N83687/001/
ə		35MG	N83687 001
/AA/		/35MG/	/N84831/001/
ə		35MG	N84831 001
/AA/		/35MG/	/N84834/001/
ə		35MG	N84834 001
/AA/		/35MG/	/N84835/001/
ə		35MG	N84835 001

PHENTERMINE RESIN COMPLEX

CAPSULE, CONTROLLED RELEASE; ORAL

IONAMIN-30			
AB	PENNWALT	EQ 30MG BASE	N11613 002
PHENTERMINE RESIN 30			
AB	QUANTUM PHARMCS	EQ 30MG BASE¤	N89120 001
			FEB 04, 1988

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

COLONLITE				
AA	DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET;		
		6.36GM/PACKET;5.53GM/PACKET;		
		21.5GM/PACKET¤	N71320 001	
			APR 20, 1988	
COLYTE				
AA	REED & CARNRICK	227.1GM/PACKET;2.82GM/PACKET;		
		6.36GM/PACKET;5.53GM/PACKET;		
		21.5GM/PACKET¤	N18983 004	
			OCT 26, 1984	

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	STERIS LABS	2MEQ/ML*	N89163 001 MAR 10, 1988

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

/BX/	/BARR/LABS/	/5MG/	/N84426/002/
	@ BARR LABS	5MG	N84426 002

PREDNISONE

TABLET; ORAL
PREDNISONE

AB	SUPERPHARM	5MG	N88865 001 OCT 25, 1984
AB		10MG	N88866 001 OCT 25, 1984
AB		20MG	N88867 001 OCT 25, 1984
/BX/		/5MG/	/N88865/001/ /OCT/25/1984/
/BX/		/10MG/	/N88866/001/ /OCT/25/1984/
/BX/		/20MG/	/N88867/001/ /OCT/25/1984/

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	QUAD PHARMS	EQ 5MG BASE/ML*	N89637 001 FEB 01, 1988
AP		EQ 5MG BASE/ML*	N89638 001 FEB 01, 1988
>ADD> AP >ADD>	STERLING DRUG	EQ 5MG BASE/ML*	N89703 001 APR 07, 1988

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL
PROMETHAZINE HCL

/BP/	/BARR/LABS/	/12.5MG/	/N84555/001/
	@ BARR LABS	12.5MG	N84555 001
/BP/		/25MG/	/N84554/001/
	@	25MG	N84554 001
/BP/		/50MG/	/N84557/001/
	@	50MG	N84557 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

/AA/	/BANMAX/PHARMS/	/65MG/	/N83184/001/
	@ BANMAX PHARMS	65MG	N83184 001
/AA/	/BARR/LABS/	/65MG/	/N83186/001/
	@ BARR LABS	65MG	N83186 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

>ADD> AB	SIDMAK LABS	10MG*	N71972 001 APR 06, 1988
>ADD> AB		20MG*	N71973 001 APR 06, 1988
>ADD> AB		40MG*	N71974 001 APR 06, 1988
>ADD> AB		60MG*	N71975 001 APR 06, 1988
>ADD> AB		80MG*	N71976 001 APR 06, 1988
>ADD> AB		90MG*	N71977 001 APR 06, 1988

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

/AP/	/UPJOHN/	/50MG/VIAL/	/N07413/001/
	@ UPJOHN	50MG/VIAL	N07413 001
		/250MG/VIAL/	/N07413/002/ /AUG/02/1984/
	@	250MG/VIAL	N07413 002 AUG 02, 1984

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUVAL

//3/VALE/CHEM/	/50MG/	/N09108/002/
BP VALE CHEM	50MG	N09108 002
//3/	/100MG/	/N09108/004/
BP	100MG	N09108 004

RESERPINE

TABLET; ORAL
RESERPINE

/BP/ /BARR/LABS/	/0.25MG/	/N80721/002/
@ BARR LABS	0.25MG	N80721 002

SECOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM SECOBARBITAL

/AB/ /BARR/LABS/	/100MG/	/N84225/001/
@ BARR LABS	100MG	N84225 001

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLODIDE 0.9% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	900MG/100ML¤	N19635 002 MAR 09, 1988

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	450MG/100ML¤	N19635 001 MAR 09, 1988

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	3GM/100ML¤	N19635 003 MAR 09, 1988
AP	TRAVENOL LABS	3GM/100ML	N19022 001 NOV 01, 1983

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	5GM/100ML¤	N19635 004 MAR 09, 1988
AP	TRAVENOL LABS	5GM/100ML	N19022 002 NOV 01, 1983

SULFAMETHOXAZOLE

TABLET; ORAL
SULFAMETHOXAZOLE

/AB/ /BARR/LABS/	/500MG/		/N87189/001/ /JUL/25/1983/
@ BARR LABS	500MG		N87189 001 JUL 25, 1983

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE

/AB/ /BARR/LABS/	/500MG/		/N84031/001/
@ BARR LABS	500MG		N84031 001

SULINDAC

TABLET; ORAL
CLINORIL

AB	MS&D	150MG		N17911 001
AB		200MG		N17911 002
	SULINDAC			
AB	DANBURY PHARMA	150MG¤	APR 03, 1990 :	N71891 001 MAR 03, 1988
AB		200MG¤	APR 03, 1990 :	N71795 001 MAR 03, 1988

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM

AB	CORD LABS	15MG¤	N71427 001 JAN 12, 1988
AB		30MG¤	N71428 001 JAN 12, 1988

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	TRAVENOL LABS	320MG/100ML	N18649 006 NOV 13, 1985

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT LABS	320MG/100ML¤	N19211 006 JAN 20, 1988

THEOPHYLLINE

TABLET, CONTROLLED RELEASE; ORAL
THEOLAIR-SR

>DLT>		/RIKER/LABS/	/250MG/	/N86363/002/	
>DLT>				/JUL/16,/1987/	
>ADD>	BC	RIKER LABS	250MG	N86363 002	
>ADD>				JUL 16, 1987	

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL
THIORIDAZINE HCL

	AB	PAR PHARM	150MG*	N89764 001
				FEB 09, 1988
	AB		200MG*	N89765 001
				FEB 09, 1988
>ADD>	AB	ROXANE LABS	25MG	N88664 001
>ADD>				MAR 15, 1984

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

	AB	PHARM BASICS	100MG*	N71355 001
				JAN 11, 1988

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

	/AB/	/BANMAX/PHARMS/	/500MG/	/N86141/001/
		@ BANMAX PHARMS	500MG	N86141 001

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
DESYREL

	AB	MEAD JOHNSON	150MG	N18207 003
				MAR 25, 1985

TRAZODONE HCL

>ADD>	AB	PUREPAC PHARM	50MG*	N71636 001
>ADD>				APR 18, 1988
>ADD>	AB		100MG*	N71514 001
>ADD>				APR 18, 1988
		TRAZON-150		
	AB	SIDMAK LABS	150MG*	N71525 001
				MAR 09, 1988

TRIAMCINOLONE

TABLET; ORAL
TRIAMCINOLONE

/BP/	/BARR/LABS/	/2MG/	/N84286/001/
	@ BARR LABS	2MG	N84286 001
/BP/		/2MG/	/N84318/001/
	@	2MG	N84318 001
/BP/		/4MG/	/N84267/001/
	@	4MG	N84267 001
/BP/		/4MG/	/N84319/001/
	@	4MG	N84319 001
/BP/		/8MG/	/N84268/001/
	@	8MG	N84268 001
/BP/		/8MG/	/N84320/001/
	@	8MG	N84320 001

TRIMETHOPRIM

TABLET; ORAL
TRIMETHOPRIM

/AB/	/BARR/LABS/	/100MG/	/N70494/001/
			/JAN/22,/1986/
	@ BARR LABS	100MG	N70494 001
			JAN 22, 1986
/AB/		/200MG/	/N70495/001/
			/MAR/14,/1986/
	@	200MG	N70495 001
			MAR 14, 1986

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
TRIPELENNAMINE HCL

/AA/	/BARR/LABS/	/50MG/	/N80744/001/
	@ BARR LABS	50MG	N80744 001

URSODIOL

CAPSULE; ORAL
DEURSIL

>ADD>	@ CIBA PHARM	150MG	N19594 001
>ADD>			DEC 31, 1987
>ADD>	@	300MG	N19594 002
>ADD>			DEC 31, 1987
	/SIPHARMEX/	/150MG/	/N19594/001/
			/DEC/31,/1987/
		/300MG/	/N19594/002/
			/DEC/31,/1987/

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOCIN HCL

AP	LILLY	EQ 1GM BASE/VIAL	N60180 002	MAR 21, 1986
AP		EQ 1GM BASE/VIAL	N62476 002	MAR 21, 1986
AP		EQ 1GM BASE/VIAL	N62716 002	MAR 13, 1987
AP		EQ 1GM BASE/VIAL	N62812 002	NOV 17, 1987

VANCOLED

AP	LEDERLE LABS	EQ 1GM BASE/VIAL¤	N62682 002	MAR 30, 1988

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

CALAN

AB	SEARLE	40MG¤	N18817 003	FEB 23, 1988
>DLT>	/SEARLE/PHARMS/	/160MG/	/N18817/004/	/FEB/23,/1988/
>ADD>	ə SEARLE PHARMS	160MG	N18817 004	FEB 23, 1988

ISOPTIN

AB	KNOLL PHARM	40MG	N18593 003	NOV 23, 1987

VERAPAMIL HCL

>ADD> AB	LEDERLE LABS	80MG¤	N71880 001	APR 05, 1988
>ADD> AB		120MG¤	N71881 001	APR 05, 1988
AB	MUTUAL PHARM	80MG¤	N71488 001	JAN 13, 1988
AB		120MG¤	N71489 001	JAN 13, 1988

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE

>ADD> AP	BULL LABS	1MG/VIAL¤	N71559 001	APR 11, 1988
>ADD> AP		2MG/VIAL¤	N71560 001	APR 11, 1988
>ADD> AP		5MG/VIAL¤	N71561 001	APR 11, 1988
>ADD> AP	QUAD PHARMS	1MG/VIAL	N71222 001	MAR 07, 1988
>ADD> AP		2MG/VIAL	N71223 001	MAR 07, 1988
>ADD> AP		5MG/VIAL	N71937 001	MAR 07, 1988

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE PFS

>ADD> AP	BULL LABS	1MG/ML¤	N71484 001	APR 19, 1988

WATER FOR INJECTION, STERILE

LIQUID; N/A

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

>ADD> AP	BAXTER	100%¤	N18632 002	APR 19, 1988
AP	KENDALL MCGAW	100%¤	N19633 001	FEB 29, 1988

ACETAMINOPHEN

SUPPOSITORY; RECTAL

TYLENOL				
MCNEIL CONSUMER	120MG	N17756 002	>DLT>	
	650MG	N17756 001	>DLT>	
/MCNEIL/LABS/	/120MG/	/N17756/002/	>ADD>	
	/650MG/	/N17756/001/	>ADD>	

IBUPROFEN

TABLET; ORAL

IBUPROFEN				
DANBURY PHARMA	200MG¤	N71905 001		
		MAR 08, 1988		
INVAMED	200MG¤	N71807 001		
		FEB 25, 1988		
MEDICOPHARMA	200MG¤	N71639 001		
		FEB 02, 1988		
>ADD> ZENITH LABS	200MG¤	N72040 001		
>ADD>		APR 29, 1988		
NUPRIN				
BRISTOL MYERS	200MG¤	N72035 001		
		FEB 16, 1988		
	200MG¤	N72036 001		
		FEB 16, 1988		
/UPJOHN/	/200MG/	/N19012/001/		
		/MAY/18,/1984/		
	/200MG/	/N19012/003/		
		/JUL/29,/1987/		
ə	200MG	N19012 001		
		MAY 18, 1984		
ə	200MG	N19012 003		
		JUL 29, 1987		

INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

MIXTARD HUMAN 70/30		
NORDISK USA	30 UNITS/ML; 70 UNITS/ML¤	N19585 001
		MAR 11, 1988

INSULIN ZINC SUSP EXTENDED BIDSYNTHETIC HUMAN

INJECTABLE; INJECTION

HUMULIN U				
/LILLY/	/40/UNITS/ML/	/N19571/001/		
		/JUN/10,/1987/		
ə LILLY	40 UNITS/ML	N19571 001		
		JUN 10, 1987		

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM A-D		
MCNEIL CONSUMER	1MG/5ML¤	N19487 001

NONOXYNOL-9

SPONGE; VAGINAL

TODAY		
/VLI/	/1GM/	/N18683/001/
		/APR/01,/1983/
WHITEHALL LABS	1GM	N18683 001
		APR 01, 1983

DRUG PRODUCTS IN THE DIVISION OF BLOOD AND BLOOD PRODUCTS / CUMULATIVE SUPPLEMENT NUMBER 4 / JAN '88 - APR '88
APPROVED UNDER SECTION 505 OF THE ACT LIST

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
MACRODEX(R)
PHARMACIA INC 6GM/100ML;0.9GM/100ML N 06826

ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL

SECTION 526 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT CONTAINS PROVISIONS WHEREBY FDA MAY DESIGNATE A SPONSOR'S DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT AS A "DESIGNATED ORPHAN DRUG". SECTION 527 OF THE ACT ESTABLISHES A PROCESS WHEREBY A SPONSOR MAY RECEIVE SEVEN YEARS OF EXCLUSIVE APPROVAL STATUS IF THAT SPONSOR IS THE FIRST TO ACHIEVE NEW DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT APPROVAL FOR A DESIGNATED ORPHAN DRUG FOR THE DESIGNATED INDICATION(S). THE EXCLUSIVE APPROVAL MAY BE REVOKED BY WRITTEN CONSENT OF THE SPONSOR OR BY FDA ACTION AFTER FINDING THAT THE SPONSOR HOLDING EXCLUSIVE APPROVAL CANNOT ASSURE THE AVAILABILITY OF SUFFICIENT QUANTITIES OF THE DRUG TO MEET THE NEEDS OF PATIENTS WITH THE DESIGNATED ORPHAN INDICATION(S).

ORPHAN DRUG EXCLUSIVE APPROVAL STATUS (CODED ODE) APPLIES ONLY TO THE APPROVED OR LICENSED INDICATION(S) FOR WHICH ORPHAN DRUG DESIGNATION HAS BEEN GRANTED PURSUANT TO SECTION 526 OF THE ACT.

FOR THE FOLLOWING DRUG PRODUCTS WITH ORPHAN DRUG EXCLUSIVE APPROVAL STATUS, THE SPONSOR HAS SEVEN YEARS OF EXCLUSIVE APPROVAL FOR THE APPROVED INDICATION BEGINNING ON THE DATE OF NDA, ANTIBIOTIC APPLICATION, OR BIOLOGICAL LICENSE APPROVAL FOR THE DRUG. NO SUBSEQUENT SPONSOR MAY RECEIVE APPROVAL OF AN NDA, BIOLOGICAL LICENSE, PAPER NDA, ANTIBIOTIC APPLICATION, ANDA, OR ABBREVIATED ANTIBIOTIC APPLICATION DURING THE SEVEN YEAR PERIOD FOR THE DRUG AND INDICATION(S) FOR WHICH ODE STATUS IS MAINTAINED UNLESS THE EXCLUSIVE APPROVAL HAS BEEN REVOKED AS DESCRIBED ABOVE OR THE SUBSEQUENT SPONSOR HAS OBTAINED WRITTEN CONSENT FROM THE SPONSOR WHO HAS RECEIVED EXCLUSIVE APPROVAL.

BIOLOGICAL PRODUCTS, ANTIBIOTICS, AND DRUGS THAT HAVE BEEN APPROVED UNDER SECTION 505 OR 507 OF THE ACT OR UNDER SECTION 351 OF THE PUBLIC HEALTH SERVICE ACT FOR MARKETING AND HAVE BEEN GIVEN ORPHAN DRUG EXCLUSIVE APPROVAL WILL BE NOTED BY THE ABBREVIATION ODE IN THE PATENT AND EXCLUSIVITY INFORMATION ADDENDUM. DRUG PRODUCTS THAT HAVE RECEIVED THE WRITTEN PERMISSION OF THE SPONSOR THAT HAS ORPHAN DRUG EXCLUSIVE APPROVAL TO BE APPROVED UNDER SECTION 527(b)(2) OF THE ACT ARE ALSO NOTED BY THE ABBREVIATION ODE IN THE PATENT AND EXCLUSIVITY INFORMATION ADDENDUM. THESE DRUG PRODUCTS DO NOT HAVE ANY EXCLUSIVE APPROVAL RIGHTS OF THEIR OWN, BUT CAN BE MARKETED BECAUSE OF THE CONSENT GIVEN BY THE SPONSOR THAT HAS EXCLUSIVE APPROVAL. THESE PRODUCTS ARE MARKED BY AN (*) NEXT TO THE APPLICANT'S NAME.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

NO APRIL 1988 APPROVALS

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO APRIL 1988 APPROVALS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR IN VIVO BIOEQUIVALENCE STUDIES AND IN VITRO DISSOLUTION TESTING AVAILABLE FROM THE DIVISION OF BIOEQUIVALENCE, HFN-250, ROOM 17B-06, 5600 FISHERS LANE, ROCKVILLE, MD 20857. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

NAME OF DRUG (DOSAGE FORM)	DATE	REVISED DATE
CARBAMAZEPINE (TABLET)	JAN 01, 1988	
CYCLOBENZAPRINE HYDROCHLORIDE (TABLET)	JAN 25, 1988	
DOXYCYCLINE HYCLATE (CAPSULE AND TABLET)	APR 11, 1988	
FENOPROFEN (CAPSULE AND TABLET)	AUG 27, 1987	FEB 03, 1988
INDOMETHACIN (CAPSULE)	JAN 27, 1988	
METAPROTERENOL SULFATE (TABLET)	MAR 18, 1988	
NORETHINDRONE; ETHINYL ESTRADIOL (TABLET)	MAR 18, 1988	

ANDA SUITABILITY PETITIONS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 5MG	87 P-0376/CP	ANABOLIC	NEW STRENGTH	APPROVED FEB 12, 1988
ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	650MG 5MG	87 P-0376/ CP0002	ANABOLIC	NEW STRENGTH	APPROVED FEB 12, 1988
CHLORZOXAZONE CAPSULE; ORAL	500MG	82 N-0032/ CP0006	MIKART	NEW DOSAGE FORM	APPROVED JAN 13, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CISPLATIN INJECTABLE; INJECTION	1MG/ML (10ML/VIAL) (50ML/VIAL) (100ML/VIAL)	87 P-0421/CP	BULL LABS	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 29, 1988
CISPLATIN INJECTABLE; INJECTION	1MG/ML (20ML/VIAL)	88 P-0010/CP	LYPHOMED	NEW DOSAGE FORM NEW STRENGTH	APPROVED APR 01, 1988
FLUOROURACIL INJECTABLE; INJECTION	50MG/ML (5ML/VIAL)	88 P-0052/CP	BEN VENUE LABS	NEW STRENGTH	APPROVED MAR 21, 1988
HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML 40MG/5ML	87 P-0399/CP	BURDITT, BOWLES, RADZIUS AND RUBERRY	NEW DOSAGE FORM	APPROVED FEB 16, 1988
HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML 80MG/5ML	87 P-0399/CP	BURDITT, BOWLES, RADZIUS AND RUBERRY	NEW DOSAGE FORM	APPROVED FEB 16, 1988
HYDROCHLOROTHIAZIDE; TRIAMTERENE TABLET; ORAL	25MG 50MG	87 P-0335/CP	PAR PHARM	NEW DOSAGE FORM	APPROVED FEB 26, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
MEPERIDINE HYDROCHLORIDE INJECTABLE; INJECTION	10MG/ML (50ML/CONTAINER)	88 P-0008/CP	LYPHOMED	NEW STRENGTH	APPROVED APR 01, 1988
PHENYTOIN SODIUM INJECTABLE; INJECTION	100MG/VIAL	87 P-0367/CP	LYPHOMED	NEW DOSAGE FORM	APPROVED FEB 16, 1988
PHENYTOIN SODIUM INJECTABLE; INJECTION	250MG/VIAL	87 P-0367/CP	LYPHOMED	NEW DOSAGE FORM	APPROVED FEB 16, 1988
VERAPAMIL HYDROCHLORIDE CAPSULE, CONTROLLED RELEASE; ORAL	120MG 240MG	87 P-0233/CP	SEARLE	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 26, 1988

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
BENZOYL METRONIDAZOLE SUSPENSION; ORAL	200MG/5ML	85 P-0258/CP	APKON LABS	NEW ESTER NEW INGREDIENT	DENIED MAR 19, 1986
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	100MG/ML (1ML/VIAL) (2ML/VIAL)	87 P-0283/CP	LYPHOMED	NEW DOSAGE FORM NEW STRENGTH	DENIED JAN 21, 1988
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	500MG/ML (1ML/VIAL) (2ML/VIAL) (4ML/VIAL)	87 P-0283/CP	LYPHOMED	NEW DOSAGE FORM NEW STRENGTH	DENIED JAN 21, 1988
METOCLOPRAMIDE HYDROCHLORIDE INJECTABLE; INJECTION	1MG/ML (50ML/VIAL)	87 P-0090/CP	INTL MEDTN SYS	NEW STRENGTH	DENIED FEB 08, 1988
METOCLOPRAMIDE HYDROCHLORIDE INJECTABLE; INJECTION	1MG/ML (75ML/VIAL)	87 P-0090/CP	INTL MEDTN SYS	NEW STRENGTH	DENIED FEB 08, 1988
METOCLOPRAMIDE HYDROCHLORIDE INJECTABLE; INJECTION	1MG/ML (100ML/VIAL)	87 P-0090/CP	INTL MEDTN SYS	NEW STRENGTH	DENIED FEB 08, 1988

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER

NEW INDICATION

I-72	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-73	FOLLICULAR STIMULATION IN VITRO FERTILIZATION

EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-26	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-27	METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-28	METHOD FOR IMPROVING MEMORY IN MAMMALS
U-29	METHOD FOR TREATING AMNESIA
U-30	METHOD OF POTENTIATING CODEINE ANALGESIA IN MAMMALS
U-31	USE IN LUNG SCANNING PROCEDURES
U-32	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-33	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS

	APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>DLT>	17920 002	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-13	MAR 31, 1991
>ADD>	17920 002	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
			3950333	APR 13, 1993		D-12	APR 30, 1989
>DLT>	17920 003	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-13	MAR 31, 1991
>ADD>	17920 003	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
			3950333	APR 13, 1993		D-12	APR 30, 1989
>DLT>	17920 004	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-13	MAR 31, 1991
>ADD>	17920 004	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
			3950333	APR 13, 1993		D-12	APR 30, 1989
>DLT>	17920 005	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-13	MAR 31, 1991
>ADD>	17920 005	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
			3950333	APR 13, 1993		D-12	APR 30, 1989
>DLT>	17924 001	CIMETIDINE HYDROCHLORIDE; TAGAMET	4024271	MAY 17, 1994		D-13	MAR 31, 1991
>ADD>	17924 001	CIMETIDINE HYDROCHLORIDE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
			3950333	APR 13, 1993		D-12	APR 30, 1989
	19309 001	ENALAPRILAT; VASOTEC	4374829	FEB 22, 2000		NDF	FEB 09, 1991
	18981 002	ENCAINIDE HYDROCHLORIDE; ENKAID	RE30811	DEC 20, 1996	U-32		
	18981 003	ENCAINIDE HYDROCHLORIDE; ENKAID	RE30811	DEC 20, 1996	U-32		
	18981 004	ENCAINIDE HYDROCHLORIDE; ENKAID	RE30811	DEC 20, 1996	U-32		
	19452 001	FLUOCINOLONE ACETONIDE; DERMA-SMOOTHE/FS				NDF	FEB 03, 1991
	18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4683235	JUL 28, 2004	U-30		
			4647591	MAR 03, 2004	U-28		
			4647591	MAR 03, 2004	U-29		
			4626549	DEC 02, 2003	U-26		
			4626549	DEC 02, 2003	U-27		
			4194009	APR 19, 1994			
	19404 001	FLURBIPROFEN SODIUM; OCUFEN	3793457	FEB 19, 1993			
	18061 001	HYDROCHLOROTHIAZIDE; TIMOLIDE 10-25	3655663	APR 11, 1989		D-2	FEB 03, 1991
	18956 003	IOHEXOL; OMNIPAQUE 300	4021481	MAY 03, 1994		I-55	FEB 01, 1988
						I-58	FEB 01, 1988
	19085 001	IPRATROPIUM BROMIDE; ATROVENT	3681500	AUG 01, 1991		NCE	DEC 29, 1991
	09048 001	METHOXSALEN; 8-MOP				I-72	MAR 23, 1991
>ADD>	19516 002	MORPHINE SULFATE; MS CONTIN				NDF	MAY 29, 1990
	18677 001	NABILONE; CESAMET	4087545	MAY 02, 1997	U-7		

	APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>DLT>	19599 001	NAFTIFINE HYDROCHLORIDE; NAFTIN	4282251	AUG 04, 1998		NCE	FEB 28, 1993
>ADD>	19599 001	NAFTIFINE HYDROCHLORIDE; NAFTIN	4282251	AUG 04, 1998		NCE	MAR 01, 1993
>ADD>	19508 001	NIZATIDINE; AXID	4382090	MAY 03, 2000	U-33		
>ADD>			4375547	MAR 01, 2000		NCE	APR 12, 1993
>ADD>	19508 002	NIZATIDINE; AXID	4382090	MAY 03, 2000	U-33		
>ADD>			4375547	MAR 01, 2000		NCE	APR 12, 1993
	19009 001	PIRBUTEROL ACETATE; EXIREL	4175128	NOV 20, 1996			
			3786160	JAN 15, 1993			
			3700681	OCT 24, 1989		NCE	DEC 30, 1991
	17881 001	TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT; TECHNETIUM TC 99M	3872226	MAR 18, 1992			
			3B63004	JAN 28, 1992	U-31		
	19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 1998	U-5	NCE	AUG 07, 1992
			4112097	SEP 05, 1995	U-5		
			4026894	MAY 31, 1994			
	19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 1998	U-5	NCE	AUG 07, 1992
			4112097	SEP 05, 1995	U-5		
			4026894	MAY 31, 1994			
	19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 1998	U-5	NCE	AUG 07, 1992
			4112097	SEP 05, 1995	U-5		
			4026894	MAY 31, 1994			
	19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 1998	U-5	NCE	AUG 07, 1992
			4112097	SEP 05, 1995	U-5		
			4026894	MAY 31, 1994			
>ADD>	18207 003	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 24, 1998			
>ADD>			4215104	JUL 29, 1997			
	19415 002	UROFOLLITROPIN; METRODIN				I-73	MAR 01, 1991
	18817 003	VERAPAMIL HYDROCHLORIDE; CALAN				I-50	DEC 16, 1989
						I-51	DEC 16, 1989
	18817 004	VERAPAMIL HYDROCHLORIDE; CALAN				I-50	DEC 16, 1989
						I-51	DEC 16, 1989

SUBSCRIPTION FORM

APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 8TH EDITION (1988)

MAIL TO:

Superintendent of Documents
Government Printing Office
Washington, DC 20402-9325
(202) 783-3238

DATE:

PURCHASER:

SHIP TO:
(If different than Purchaser)

CONTACT:

TELEPHONE *(Include Area Code)*:

METHOD OF PAYMENT:

☐ Charge my GPO Account No. _____

☐ Purchase Order No. _____

☐ Check/money order enclosed for $ _____
(Make check or money order payable to Superintendent of Documents)

AUTHORIZING SIGNATURE:

DATE:

DESCRIPTION	QUANTITY	UNIT PRICE	TOTAL PRICE
The 8th Edition is published in March 1988. Subscription includes the Approved Drug Products publication and monthly Cumulative Supplements. DOMESTIC (Stock No. 917-001-00000-6)		@ $79.00	$
FOREIGN (Stock No. 917-001-00000-6)		@ $98.75	$
ENTER TOTAL			$